RecruitingNCT05471011

COVID-19 Outcome Prediction Algorithm

Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients


Sponsor

University of California, Los Angeles

Enrollment

600 participants

Start Date

Aug 8, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in hospitalized COVID-19 patients broadly reflecting US demographics who are at increased risk of adverse outcomes from COVID-19 using both clinical and molecular data. We will enroll patients from a hospitalized civilian population in one of the country's largest metropolitan areas and a representative National Veteran's population.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Symptomatic COVID-19 infection with hospital admission
  • Age 18 and above
  • Informed consent

Exclusion Criteria3

  • Absence of symptomatic COVID-19 infection with hospital admission
  • Age 17 or below
  • No informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood and nasal swab sampling

Blood and nasal swab sampling


Locations(7)

VA Greater Los Angeles Healthcare System

Los Angeles, California, United States

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Olive View-UCLA Education & Research Institute

Sylmar, California, United States

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance, California, United States

Atlanta VA Medical Center

Decatur, Georgia, United States

Bronx VA Medical Center

The Bronx, New York, United States

Michael E. DeBakey VA Medical Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05471011


Related Trials